Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the …
![LYBALVI Long-Term Study: Sustained Safety and Efficacy](https://i0.wp.com/globalpharmalive.com/wp-content/uploads/2024/01/pexels-darya-sannikova-4603576.jpg?resize=760%2C427&ssl=1)
![LYBALVI Long-Term Study: Sustained Safety and Efficacy](https://i0.wp.com/globalpharmalive.com/wp-content/uploads/2024/01/pexels-darya-sannikova-4603576.jpg?resize=760%2C427&ssl=1)
Pharma News From Around The World
Pharma News From Around The World
Pharma News From Around The World
Alkermes plc (Nasdaq: ALKS) today announced topline results from a phase 3, open-label extension study assessing the …